These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 8859263)

  • 1. Clinical and hematologic effects of hydroxyurea in children with sickle cell anemia.
    Jayabose S; Tugal O; Sandoval C; Patel P; Puder D; Lin T; Visintainer P
    J Pediatr; 1996 Oct; 129(4):559-65. PubMed ID: 8859263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
    Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hydroxyurea therapy in children severely affected with sickle cell disease.
    Scott JP; Hillery CA; Brown ER; Misiewicz V; Labotka RJ
    J Pediatr; 1996 Jun; 128(6):820-8. PubMed ID: 8648542
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia.
    Wang WC; Wynn LW; Rogers ZR; Scott JP; Lane PA; Ware RE
    J Pediatr; 2001 Dec; 139(6):790-6. PubMed ID: 11743503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of hydroxyurea in children ages 2 to 5 years with sickle cell disease.
    Hoppe C; Vichinsky E; Quirolo K; van Warmerdam J; Allen K; Styles L
    J Pediatr Hematol Oncol; 2000; 22(4):330-4. PubMed ID: 10959903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease.
    Jain DL; Sarathi V; Desai S; Bhatnagar M; Lodha A
    Hemoglobin; 2012; 36(4):323-32. PubMed ID: 22734586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three-year follow-up of hydroxyurea treatment in severely ill children with sickle cell disease. The French Study Group on Sickle Cell Disease.
    de Montalembert M; Belloy M; Bernaudin F; Gouraud F; Capdeville R; Mardini R; Philippe N; Jais JP; Bardakdjian J; Ducrocq R; Maier-Redelsperger M; Elion J; Labie D; Girot R
    J Pediatr Hematol Oncol; 1997; 19(4):313-8. PubMed ID: 9256830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece.
    Loukopoulos D; Voskaridou E; Kalotychou V; Schina M; Loutradi A; Theodoropoulos I
    Blood Cells Mol Dis; 2000 Oct; 26(5):453-66. PubMed ID: 11112383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment.
    Steinberg MH; Barton F; Castro O; Pegelow CH; Ballas SK; Kutlar A; Orringer E; Bellevue R; Olivieri N; Eckman J; Varma M; Ramirez G; Adler B; Smith W; Carlos T; Ataga K; DeCastro L; Bigelow C; Saunthararajah Y; Telfer M; Vichinsky E; Claster S; Shurin S; Bridges K; Waclawiw M; Bonds D; Terrin M
    JAMA; 2003 Apr; 289(13):1645-51. PubMed ID: 12672732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy.
    Ware RE; Eggleston B; Redding-Lallinger R; Wang WC; Smith-Whitley K; Daeschner C; Gee B; Styles LA; Helms RW; Kinney TR; Ohene-Frempong K
    Blood; 2002 Jan; 99(1):10-4. PubMed ID: 11756146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systematic review: Hydroxyurea for the treatment of adults with sickle cell disease.
    Lanzkron S; Strouse JJ; Wilson R; Beach MC; Haywood C; Park H; Witkop C; Bass EB; Segal JB
    Ann Intern Med; 2008 Jun; 148(12):939-55. PubMed ID: 18458272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydroxyurea in sickle cell disease patients from Eastern Saudi Arabia.
    Al-Jam'a AH; Al-Dabbous IA
    Saudi Med J; 2002 Mar; 23(3):277-81. PubMed ID: 11938415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A clinically meaningful fetal hemoglobin threshold for children with sickle cell anemia during hydroxyurea therapy.
    Estepp JH; Smeltzer MP; Kang G; Li C; Wang WC; Abrams C; Aygun B; Ware RE; Nottage K; Hankins JS
    Am J Hematol; 2017 Dec; 92(12):1333-1339. PubMed ID: 28913922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of hydroxyurea in sickle cell anemia: a clinical trial in children and teenagers with severe sickle cell anemia and sickle cell beta-thalassemia.
    Koren A; Segal-Kupershmit D; Zalman L; Levin C; Abu Hana M; Palmor H; Luder A; Attias D
    Pediatr Hematol Oncol; 1999; 16(3):221-32. PubMed ID: 10326220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanism of action of hydroxyurea in the management of sickle cell anemia in adults.
    Charache S
    Semin Hematol; 1997 Jul; 34(3 Suppl 3):15-21. PubMed ID: 9317197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hydroxycarbamide for sickle-cell anaemia in infancy.
    Weatherall DJ
    Lancet; 2011 May; 377(9778):1628-30. PubMed ID: 21571132
    [No Abstract]   [Full Text] [Related]  

  • 17. Enhancing Effect of Hydroxyurea on Hb F in Sickle Cell Disease: Ten-Year Egyptian Experience.
    Youssry I; Abdel-Salam A; Ismail R; Bou-Fakhredin R; Mohamed Samy R; Ezz El-Deen F; Taher AT
    Hemoglobin; 2017; 41(4-6):267-273. PubMed ID: 29251012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of hydroxyurea on blood rheology in sickle cell anemia: A two-years follow-up study.
    Lemonne N; Möckesch B; Charlot K; Garnier Y; Waltz X; Lamarre Y; Antoine-Jonville S; Etienne-Julan M; Hardy-Dessources MD; Romana M; Connes P
    Clin Hemorheol Microcirc; 2017; 67(2):141-148. PubMed ID: 28759962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydroxyurea dose optimisation for children with sickle cell anaemia in sub-Saharan Africa (REACH): extended follow-up of a multicentre, open-label, phase 1/2 trial.
    Aygun B; Lane A; Smart LR; Santos B; Tshilolo L; Williams TN; Olupot-Olupot P; Stuber SE; Tomlinson G; Latham T; Ware RE;
    Lancet Haematol; 2024 Jun; 11(6):e425-e435. PubMed ID: 38701812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydroxyurea for the treatment of sickle cell anemia.
    Platt OS
    N Engl J Med; 2008 Mar; 358(13):1362-9. PubMed ID: 18367739
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.